title: Regenerative cell therapy and pharmacotherapeutic intervention in heart failure: Part 1: Cardiovascular progenitor cells, their functions and sources.
abstract: It has been postulated that bone marrow derived endothelial progenitor cells (BM-EPCs) are essential for neovascularisation and endothelial repair and are involved in pharmacological treatment, and even its potential targets. There is no doubt that the ultimate success of angiogenic cell therapy will be determined by an appropriate stimulation of certain angiogenic progenitor cell subpopulations. Unfortunately, the biology of EPCs is still poorly understood. In particular, the understanding of endogenous microenvironments within the progenitor cell niches is critical, and will provide us with information about the signalling systems that supply a basis to develop rational pharmacotherapy to enhance the functional activity of endogenous or transplanted progenitor cells. The final success of clinical improvement of progenitor cell-mediated vascular repair and angiogenic therapy depends on a better understanding of EPC biology and a smart therapeutic design. In the first part of this review we first briefly discuss the possible involvement of progenitor cells in chronic heart failure. In part 2 we focus on factors that beneficially affect BMEPCs, with an emphasis on pharmacological molecular pathways involved in BM-EPC-induced neovascularisation. (Neth Heart J 2008;16:305-9.).
authors.affiliation: Department of Experimental Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
authors.forename: C
authors.initials: C
authors.lastname: Qian
authors.forename: R G
authors.initials: RG
authors.lastname: Schoemaker
authors.forename: W H
authors.initials: WH
authors.lastname: van Gilst
authors.forename: B
authors.initials: B
authors.lastname: Yu
authors.forename: A J M
authors.initials: AJ
authors.lastname: Roks